Real-life data on pasireotide in monotherapy or combined in active Cushing's disease.

Front Endocrinol (Lausanne) · 2025 · PMC12657153 · PMID 41323967

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Three patients started/increased lipid-lowering treatment, while five patients maintained the same therapy and showed a trend of LDLc reduction (108.6 mg/dL vs. 88.6 mg/dL, p = 0.06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.